Author

Mickaël Guilbaud

InsermORCID 0000-0001-6853-7013Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Nicolas JauliniD· 3 shared Oumeya AdjaliiD· 3 shared David DeniaudiD· 2 shared Dimitri Álvarez‐DortaiD· 2 shared Karine PavageauiD· 2 shared Maia MarchandiD· 2 shared Mathieu MéveliD· 2 shared Mohammed Bouzelha· 2 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBioengineering

Nicolas JaulinORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BioengineeringBiomedicine & PharmacotherapyPeer-reviewedFeb 5, 2026

Ultrafast tyrosine-based cell membrane modification via diazonium salts: a new frontier for biomedical applications

Mohammed Bouzelha, Karine Pavageau, Sarah Renault…·Mathieu Mével

This paper introduces an ultrafast method for cell membrane modification using diazonium salts, enabling efficient and safe functionalization of various cell types for biomedical applications.

DOI 10.1016/j.biopha.2026.119095

humanproteomics

𝕏 PostBluesky

BioengineeringBiomedicine & PharmacotherapyPeer-reviewedJun 27, 2025

Advancing Liver Gene Therapy: Enhanced Transduction with GalNAc-Bioconjugated rAAV Capsids

Pierre-Alban Lalys, Audrey Bourdon, Mohammed Bouzelha…·David Deniaud

This study enhances liver gene therapy by conjugating GalNAc to rAAV capsids, improving transduction efficiency in mice while reducing required dosages.

2 citations

mouseexperimental assay

𝕏 PostBluesky

ImmunologyHuman Gene TherapyPeer-reviewedApr 6, 2024

Prevalence study of cellular capsid-specific immune responses to AAV2, 4, 5, 8, 9 and rh10 in healthy donors

Rebecca Xicluna, Allan Avenel, Céline Vandamme…·Gwladys Gernoux

The paper assesses T cell immunity to various AAV serotypes in healthy donors, finding AAV9 has the highest prevalence of pre-existing cellular immunity.

14 citations

humanexperimental assay

𝕏 PostBluesky